#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rheumatoid arthritis Subdural haematoma Superficial vein thrombosis Proteus syndrome Antisynthetase syndrome Hodgkin's disease Transient ischaemic attack Chondrosarcoma metastatic Congenital growth hormone deficiency Vitamin B12 deficiency Neuropathic arthropathy Soft tissue sarcoma Cushing's syndrome Breast angiosarcoma Primary amyloidosis More trials…

    Learn about Rare Diseases

    Pemphigoid – Diagnostics Pituitary-dependent Cushing’s syndrome – Life with Disease Idiopathic inflammatory myopathy – Basic Information Immunodeficiency congenital – Treatment Marfan’s syndrome Rhabdoid tumour – Treatment Ehlers-Danlos syndrome – Basic Information Inclusion body myositis – Basic Information Pituitary-dependent Cushing’s syndrome Hereditary motor and sensory neuropathy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lolium Perenne Pollen Extract PALAZESTRANT Cenerimod Potato Starch Garadacimab POLYSORBATE 80 Colecalciferol FLUORIDE Spiramycin Nefopam Reboxetine Efzofitimod Cls12311 Inaxaplin Tecovirimat Vitamin A Bp Clofazimine Mesalazine Xtmab-16 Pelacarsen More therapies…

    Learn about Your Condition

    Aphthous ulcer Breast angiosarcoma Solitary fibrous tumour Familial hypertriglyceridaemia Non-obstructive cardiomyopathy Schizophrenia Hypoglycaemia Adenovirus infection Rectal cancer Tuberculosis Nocturia Chronic myeloid leukaemia Myocardial ischaemia Craniotomy Metastatic gastric cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Glucose
    • Monalizumab
    • Oleclumab
    France Germany Italy Poland Portugal Spain

  • Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +1

  • Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

    Not recruiting

    3 1
    Investigated Diseases:
    • Autonomic nervous system imbalance
    • Hot flush
    Investigated Drugs:
    • Elinzanetant
    Austria Belgium Finland France Germany Hungary +6

  • Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

    Not recruiting

    3 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Xevinapant
    Austria Belgium Czechia France Germany Greece +6

  • Study on the Safety and Effectiveness of Vepdegestrant and Samuraciclib for Adults with ER+ Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Samuraciclib
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    Belgium France Italy Spain

  • Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer recurrent
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Ociperlimab
    • Pembrolizumab
    • Tislelizumab
    France Germany Italy The Netherlands Poland Spain

  • Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Haematological malignancy
    • Neoplasm malignant
    Investigated Drugs:
    • Ociperlimab
    • Pamiparib
    • Tislelizumab
    France Italy Poland

  • Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Actinium (Ac 225) Oxodotreotide
    • Everolimus
    • L-Arginine Hydrochloride
    Belgium France The Netherlands Spain

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epirubicin
    • Olaparib
    • Capecitabine
    Austria Belgium Bulgaria France Germany Hungary +3

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    Austria Belgium France Germany Hungary Iceland +6
Previous Page
1 … 16 17 18 19 20 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!